Which “innovator” patent covers deflazacort suspension?
Deflazacort is a corticosteroid, and “deflazacort suspension” is a branded oral liquid formulation used to deliver the drug as a suspension rather than tablets. The patent you’re likely looking for as the “innovator” (first-originator) protection is typically the original brand’s active-drug (or formulation) patents plus later patents covering specific improvements (such as the suspension formulation, particle/crystal properties, or manufacturing process).
However, the provided prompt doesn’t include any specific brand name (for example, whether you mean Emflaza or another market-specific product), patent numbers, jurisdictions (US, EP, India, etc.), or the exact wording of the patent claim. Patent status and the “innovator” designation vary by country and by whether you mean:
- the first patent that protected the drug substance,
- a later patent for the suspension formulation, or
- the first patent currently listed for regulatory exclusivity in a specific market.
To identify the correct innovator patent, you need at least one of the following: the brand name of the suspension, the country/regulatory system you care about, or a patent number/application number.
Are deflazacort suspension patents about the drug itself or the liquid formulation?
In most cases, patent protection for an oral suspension focuses on the formulation or manufacturing, such as:
- how deflazacort is dispersed or stabilized in the suspension,
- particle size/solid-state form controls that affect dissolution and bioavailability,
- excipients and their ratios,
- manufacturing process controls that keep the drug suspended and stable.
Drug-substance patents (covering the molecule) usually expire earlier than formulation-specific patents (covering how the drug is presented), which is why suspension-specific patents can remain relevant for longer in some jurisdictions.
How do you find the innovator patent for a specific deflazacort suspension brand in the US/Europe/India?
Search strategies that usually work:
- Start with the brand label and then look up the brand’s “Orange Book” listing (US) or the relevant regulatory exclusivity database for the region you care about.
- Identify patents tied to the approved product (not just the drug in general).
- Separate “active ingredient” patents from “formulation/product” patents, since the suspension wording often maps to product/formulation patents.
If you tell me the country and the brand name of deflazacort suspension you mean, I can narrow it to the specific innovator patent(s) that regulators list as covering that exact product.
What happens to deflazacort suspension exclusivity if patents expire or get challenged?
When patents expire or are overturned, generic or biosimilar-style competitors (for small-molecule generics, typically “generic deflazacort” rather than biosimilars) can enter, subject to:
- whether any formulation-specific patents still block approval,
- whether regulatory exclusivity (not just patents) has expired,
- whether there are remaining litigation or stays that affect market entry.
Patent litigation and “paragraph IV”-type challenges (in the US) can delay entry even after a patent’s legal challenge begins.
What I need from you to answer with a specific patent number
Reply with any one of these, and I’ll target the innovator patent precisely:
1) the brand name of the deflazacort suspension (and the country), or
2) the patent office/jurisdiction (US, EP, UK, India, etc.), or
3) a patent number/application number you suspect is the one.
Sources
No sources were provided in the prompt, so I can’t cite specific innovator patent records yet.